New and updated preclinical and clinical data presented by biopharma firms at the American Society of Clinical Oncology annual meeting, including: Antengene, Dizal, Harbour Biomed, I-Mab, Immutep, Inxmed, Kazia, Seagen, Takeda, Transcenta.